<DOC>
	<DOCNO>NCT00081913</DOCNO>
	<brief_summary>The purpose study determine cell therapy cell ( autologous cell ) deliver catheter region heart poor blood flow safe relieve chest pain and/or ability exercise .</brief_summary>
	<brief_title>Stem Cell Study Patients With Heart Disease</brief_title>
	<detailed_description>The goal study determine safety various dos autologous ( one 's ) stem cell , deliver catheter region heart poor blood flow . Stem cell primitive cell produce bone marrow develop blood cell type cell . In addition determine whether new approach safe , diagnostic test may offer preliminary insight usefulness approach treat myocardial ischemia ( condition area heart lack enough oxygen blood flow keep heart muscle work well ) . This blind , randomize study compare certain type stem cell call CD34-positive versus placebo agent ( normal saline ) . You 3:1 chance receive CD34-positive stem cell versus placebo agent ( normal saline ) . You know whether receive CD34-positive cell placebo agent ( normal saline ) . If randomize receive placebo ( normal saline ) , undergo pre-treatment phase study ( include stem cell mobilization phase apheresis procedure ) , rather receive injection CD34-positive cell , receive injection placebo agent ( normal saline ) . There research evidence suggest CD34-positive cell may help develop new blood vessel improve blood flow inject directly heart muscle .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Chest Pain</mesh_term>
	<criteria>Subjects functional class ( CCS ) III IV angina . Subjects attempt `` best '' medical therapy without control symptom . All subject must recent coronary angiogram ( within last 3 month ) . Clinical sign symptom clinically significant ischemia nuclear perfusion image . Subjects must able complete minimum 1 minute 6 minute Standard Bruce Protocol . Subject experience angina baseline exercise tolerance test . Subjects must either longer capable reproduction take acceptable measure prevent reproduction study . Normal renal function . Normal liver function . Normal blood count . Angiographic Inclusions : Total occlusion epicardial coronary artery . Candidates high risk percutaneous coronary angioplasty treatment zone ( ) base upon clinical anatomic consideration include limited following : diabetes , congestive heart failure ( severe right heart failure , NYHA class III IV ) , leave main disease , pulmonary hypertension , severe proximal vessel tortuosity , severe bendpoint obstruction , diffuse disease ( &gt; 2 cm length ) , small vessel ( &lt; 2 mm reference diameter ) , stenosis either diffuse ( &gt; 2 cm length ) distal , incessant restenosis lesion , unfavorable bifurcation stenosis , degenerate thrombose saphenous vein graft . Predominant congestive heart failure symptom . Patients hospitalize primary diagnosis CHF prior 6 month . Patients diuretic add medical regimen increase diuretic dosage sign symptom CHF past 6 month . Patients leave ventricular ejection fraction le 25 % determine transthoracic echocardiography . Patients physical finding consistent ongoing uncontrolled CHF . Myocardial infarction within 30 day treatment . Successful coronary revascularization procedure within 3 month study enrollment . Documented stroke transient ischemic attack ( TIA ) within 60 day study enrollment . History severe aortic stenosis insufficiency ; severe mitral stenosis ; severe mitral insufficiency . Severe comorbidity associate reduction life expectancy le 1 year . Subjects PT , PTT platelet count great upper limit normal hematocrit &lt; 35 % . Subjects uncontrolled hypertension . Currently enrol another investigational device drug trial ( IDE IND ) complete required followup period . History alcohol drug abuse within 3 month screen . Joint peripheral vascular disease severely limit treadmill walk . Chronic obstructive pulmonary disease severely limit walk FEV1.0 &lt; 30 % predict . Subjects pregnant lactating . Males females capable reproduction take acceptable measure prevent reproduction study . Subjects test positive HIV , hepatitis B hepatitis C , chronic inflammatory disease , autoimmune disease chronic immunosuppressive medication . Subjects know hypersensitivity E. coliderived protein . Subjects evidence ( clinical , laboratory , image ) cancer recurrence within past 5 year ( nonmelanoma skin cancer situ cervical carcinoma ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Apheresis</keyword>
	<keyword>Cell Transfer</keyword>
	<keyword>Chest Pain</keyword>
	<keyword>Adult Stem Cell Therapy</keyword>
</DOC>